Results 191 to 200 of about 214,511 (232)
Some of the next articles are maybe not open access.
Antifungal Prophylaxis in Lung Transplant Recipients
Transplantation, 2016Invasive fungal infection remains a serious postoperative complication in lung transplant recipients and is associated with significant morbidity and mortality. Although most lung transplant centers use antifungal prophylaxis, consensus on the strategy, choice of antifungal agent(s), route of administration, and duration of prophylaxis have not been ...
Twisha S, Patel +3 more
openaire +2 more sources
Antifungal Prophylaxis in Lung Transplantation
Seminars in Respiratory and Critical Care Medicine, 2011Fungal infections are among the most serious complications of lung transplantation. The 1-year cumulative incidence of invasive fungal infections in lung transplant recipients is 6 to 10%, which is higher than most other solid organ transplant recipients. Aspergillus spp.
openaire +2 more sources
Oral antifungals as prophylaxis in haematological malignancy
Blood Reviews, 2001In the standard treatment of patients with haematological malignancy, immunosuppressive therapy produces prolonged periods of neutropenia and mucositis, which increase the risk of systemic fungal infection. In allogeneic bone marrow transplantation, this risk extends well beyond the period of neutropenia when graft-versus-host disease, and its ...
Prentice, A.G., Donnelly, J.P.
openaire +3 more sources
Febrile neutropenia: antifungal prophylaxis
International Journal of Antimicrobial Agents, 2000Despite being widely practised there is little or no evidence to support the use of antifungal prophylaxis in febrile nuetropenic patients. With the greater recognition of risk factor, the increasing readiness to use imaging techniques such as the high-resolution CT scan and new methods for detecting fungi such as Aspergillus galactomannan on the one ...
openaire +2 more sources
Antifungal Prophylaxis in Bone Marrow Transplant
Annals of Pharmacotherapy, 1995The benefits of fungal prophylaxis with fluconazole in BMT patients appear to outweigh the risks of a possible increase in colonization and infection by C. krusei or T. glabrata. Disseminated fungal infections caused by C. tropicalis and C. albicans have a 38.8% mortality rate, and these infections may be prevented by the prophylactic use of ...
H H, Lam, B L, Althaus
openaire +2 more sources
Antifungal Prophylaxis in Haematology
2009Invasive fungal diseases are a source of significant morbidity and mortality in patients with haematological malignancies, particularly those with prolonged and severe neutropenia. In view of the poor prognosis associated with tardy treatment initiation, antifungal prophylaxis has become increasingly popular.
Maria J.G.T. Rüping +2 more
openaire +1 more source
Antifungal Prophylaxis and Pre-Emptive Therapy
Drugs, 2009In recent years, several reports have underlined the increasing role of fungal infections as a cause of morbidity and mortality in hospitalized non-haematological patients. For this reason, and also in light of the high mortality rate associated with these infections, chemoprophylaxis has been advocated for surgical patients hospitalized in intensive ...
openaire +3 more sources
Antifungal prophylaxis in solid organ transplant recipients
Expert Review of Anti-infective Therapy, 2011Solid organ transplantation is life saving for thousands of patients worldwide with end-stage organ failure, but post-transplantation invasive fungal infections (IFIs) remain a significant cause of morbidity and mortality. To improve patient outcomes, investigators have explored various strategies of prevention, including the use of antifungal ...
Kyle D, Brizendine +2 more
openaire +2 more sources
Antifungal prophylaxis and treatment in patients with hematological malignancies
Expert Review of Anti-infective Therapy, 2010Invasive fungal infection (IFI) is a serious and common complication in hematological patients. The risk is highest among acute leukemia patients undergoing induction chemotherapy and patients undergoing allogeneic hematopoietic stem-cell transplantation. Owing to the difficulty in diagnosing IFIs and the fatality rate associated with delayed treatment,
Liang, R, Hwang, YY
openaire +4 more sources
Variation in antifungal prophylaxis strategies in lung transplantation
Transplant Infectious Disease, 2006Abstract: We conducted a survey of 50 lung transplant centers across the world to evaluate the variation in antifungal prophylaxis practices. These 50 centers performed 63% of the world's lung transplants reported in 2001. Eighty‐six percent (43/50) of the centers responded to the survey. Sixty‐nine percent (30/43) of centers used universal antifungal
Husain, S. +5 more
openaire +5 more sources